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The pathology of a patient’s breast carcinoma can be highly
indicative of BRCA1 mutation status. Compared to sporadic
and BRCA2 deficient breast carcinomas, BRCA1 deficient
carcinomas tend to be estrogen receptor (ER) negative,
progesterone receptor (PR) negative, HER2 negative, cyto-
keratin (CK)5/6 positive, and CK14 positive [1,2]. BRCAPRO
is an accurate, widely used risk prediction model that esti-
mates the probability that an individual carries a deleterious
germline mutation in BRCA1 or BRCA2  based upon their
personal and/or family history of breast and ovarian cancer.
Recently, when BRCAPRO carrier probabilities were up-
dated using a patient’s pathological sub-type, in a two-step
process, risk estimation was improved [3]. Here we describe
how we have substantially improved BRCAPRO by directly
integrating marker information into the estimation of carrier
probabilities and cancer risk.
The theory underlying BRCAPRO is described elsewhere
[4,5]. Briefly, the model transforms information on mutation
frequency, disease penetrance, and Mendelian transmission
patterns into gene carrier probabilities through application of
Bayes’ rule. For unaffected individuals the model predicts
cancer risk from a weighted average of the penetrance for
mutation carriers and non-carriers, with the estimated carrier
probabilities as weights. The derived conditional probability of
the marker status given carrier status used in our calculations
were obtained from published data [1,2] and are presented in
Table 1. These conditional probabilities are derived from a
single study and from a highly selected group of high-risk
breast cancer families and thus should be interpreted with
some care. The following assumptions were made about the
use of markers in combination. First, for ER negative tumors,
carrier probabilities were updated using CK5/6 and CK14
status, if available. PR status does not influence carrier
predictions if ER status is included because of a strong
correlation between ER and PR. Second, Her-2 neu status
was not used because it was not predictive of marker status
after accounting for ER [1]. Third, marker information was
assumed not to be associated with BRCA2 mutation status,
because  BRCA2 and sporadic tumors have similar marker
profiles. Updating BRCA1 probability can have a residual
impact on the BRCA2 carrier probability.
Our updated software package is freely available from [6,7].
A clinical example of a 54 year old female counselee with
breast cancer at 45 whose mother had breast cancer at age
63 and no other family history, under various marker
scenarios, is presented in Table 2. Without marker data, the
counselee’s carrier probabilities for BRCA1 and BRCA2 are
2.2% and 2.3%, respectively. These probabilities are 5.5% if
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CK = cytokeratin; ER = estrogen receptor; PR = progesterone receptor.
Table 1
Conditional probability of marker status given carrier status
Marker status given 
Marker status carrier status
ER CK14 CK5/6 PR BRCA1 Non-BRCA1
+.. . 0.1 0.65
–++ . 0.438 0.016
–+– . 0.124 0.048
––+ . 0.134 0.024
––– . 0.209 0.24
...+ 0.21 0.63
Estimates obtained from Lakhani and colleagues [1]. Plus signs (+)
denote positive; hyphens (–) denote negative; periods (.) denote missing.Page 2 of 2
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her tumor is ER negative or 0.35% if ER positive. Changes in
carrier probability generally correspond to markedly different
clinical recommendations regarding genetic testing and
cancer prevention. Including this information greatly impacts
BRCAPRO carrier probabilities and improves distinction
between BRCA1 and non-BRCA1 breast tumors.
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Table 2
Example of clinical application: BRCA1 and BRCA2 carrier probabilities (%) under selected marker profile scenarios
Cancer history
Estimated
Counselee: 54 year old with breast cancer at 45 Mother: breast cancer at 63 carrier probabilities (%)
ER CK14 CK5/6 PR ER CK14 CK5/6 PR BRCA1 BRCA2
.. . . . . . .2.2 2.3
–.. . . . . .5.5 2.3
+... . . . .0.35 2.4
.. . - . . . .4.6 2.3
.. . + . . . . 0.75 2.4
–+ + .... . 38 1.5
–.. . - . . .11 2.1
–.. . + . . .2.1 2.3
–+ + . – + + . 36 1.5
–+ –. – + – +2.1 2.3
No other family history is available. Plus signs (+) denote positive; hyphens (–) denote negative; periods (.) denote missing.